title: Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin.
abstract: The pharmacokinetics of vinblastine were studied in 16 patients with non-small cell lung cancer after a bolus intravenous dose of 3 mg/m2 given before or after cisplatin (100 mg/m2). Venous blood was collected at 0, 10, and 36 hr for analysis by radioimmunoassay. The mean plasma vinblastine concentration at 10 hr was similar when vinblastine was given before (4.8 ng/ml; 95% CI, 3.2-6.3) or after cisplatin (4.9 ng/ml; 95% CI, 2.7-7.1). Plasma vinblastine concentrations in patients given cisplatin were higher than previously reported in patients given vinblastine alone. Patients with plasma vinblastine concentrations less than 2.75 ng/ml at 10 hr experienced less severe neutropenia (37% fall in neutrophil count; 95% CI, 18-55) than those with levels greater than 2.75 ng/ml (69% fall in neutrophil count; 95% CI, 62-77). In conclusion, the pharmacokinetics of vinblastine predict the severity of neutropenia and may be altered when given in conjunction with cisplatin.
authors.affiliation: Prince of Wales Hospital, New South Wales, Sydney, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Links
authors.forename: S
authors.initials: S
authors.lastname: Watson
authors.forename: K
authors.initials: K
authors.lastname: Lethlean
authors.forename: W
authors.initials: W
authors.lastname: Aherne
authors.forename: F
authors.initials: F
authors.lastname: Kirsten
authors.forename: S
authors.initials: S
authors.lastname: Clarke
authors.forename: M
authors.initials: M
authors.lastname: Law
authors.forename: M
authors.initials: M
authors.lastname: Friedlander
authors.forename: P
authors.initials: P
authors.lastname: Galettis
authors.forename: M J
authors.initials: MJ
authors.lastname: McKeage
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007958:Leukocyte Count / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009504:Neutrophils / Q000187:drug effects; D011863:Radioimmunoassay; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D002945:Cisplatin